Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Non Hodgkins Lymphoma Nhl Pipeline Insight

Non-Hodgkin's Lymphoma (NHL) Overview

"Non-Hodgkin's Lymphoma (NHL) Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Non-Hodgkin's Lymphoma market. A detailed picture of the NHL pipeline landscape is provided, which includes the disease overview and NHL treatment guidelines. The assessment part of the report embraces in-depth NHL commercial assessment and clinical assessment of the Non-Hodgkin's Lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Hodgkin's Lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Geography Covered

  • Global coverage


Non-Hodgkin's Lymphoma Understanding

Non-Hodgkin's Lymphoma Overview


Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphatic system. It occurs when tumors develop from the lymphocytes. A lymphocyte is a type of white blood cell. NHL is more common than Hodgkin’s lymphoma. The main difference between Hodgkin’s lymphoma and NHL is the presence of a type of abnormal cell called the Reed-Sternberg cell. This type of abnormal cell is only present in Hodgkin’s lymphoma. Hodgkin’s lymphoma and NHL have very different treatment options. Many types of cancers can spread to the lymph nodes. However, only cancers that start in the lymph tissue are considered lymphomas. Non-Hodgkin lymphoma is divided into more than 30 types, classified based on the type of lymphocyte involved: B lymphocytes (B cells) or T lymphocytes (T cells). Non-Hodgkin lymphoma is further classified by other factors, including whether it is aggressive (fast-growing) or indolent (slow-growing).


Non-Hodgkin’s lymphoma Symptoms


The symptoms of NHL may include abdominal pain or swelling, chest pain, coughing, difficulty breathing, swollen lymph nodes, fatigue, fever, night sweats, and weight loss.


Non-Hodgkin’s lymphoma Classification


There are many different types of non-Hodgkin lymphoma (NHL), so classifying it can be quite confusing (even for doctors). Several different systems have been used, but the most recent system is the World Health Organization (WHO) classification. The WHO system groups lymphomas based on:


  • The type of lymphocyte the lymphoma starts in
  • How the lymphoma looks under a microscope
  • The chromosome features of the lymphoma cells
  • The presence of certain proteins on the surface of the cancer cells


Non-Hodgkin’s lymphoma Treatment


Depending on the type and stage (extent) of the lymphoma and other factors, treatment options for people with NHL might include: Chemotherapy for Non-Hodgkin Lymphoma, Immunotherapy for Non-Hodgkin Lymphoma, Targeted Therapy Drugs for Non-Hodgkin Lymphoma, Radiation Therapy for Non-Hodgkin Lymphoma, High-Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin Lymphoma, Surgery for Non-Hodgkin Lymphoma.


Non-Hodgkin's Lymphoma of pipeline development activities 

The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Non-Hodgkin's Lymphoma with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Non-Hodgkin's Lymphoma treatment.
  • Non-Hodgkin's Lymphoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Non-Hodgkin's Lymphoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  


Non-Hodgkin's Lymphoma (NHL) Analytical Perspective by DelveInsight

  • In-depth Non-Hodgkin's Lymphoma (NHL) Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Non-Hodgkin's Lymphoma (NHL) Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.


Scope of the report

  • The Non-Hodgkin's Lymphoma (NHL) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Non-Hodgkin's Lymphoma (NHL) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Non-Hodgkin's Lymphoma (NHL) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Non-Hodgkin's Lymphoma (NHL) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Non-Hodgkin's Lymphoma (NHL).


Report highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Non-Hodgkin's Lymphoma (NHL).    
  • In the coming years, the Non-Hodgkin's Lymphoma (NHL) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Non-Hodgkin's Lymphoma (NHL) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Non-Hodgkin's Lymphoma (NHL) treatment market. Several potential therapies for Non-Hodgkin's Lymphoma (NHL) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Non-Hodgkin's Lymphoma (NHL) market size in the coming years.  
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Non-Hodgkin's Lymphoma (NHL)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 


Key Questions

  • What are the current options for Non-Hodgkin's Lymphoma (NHL) treatment?
  • How many companies are developing therapies for the treatment of Non-Hodgkin's Lymphoma (NHL)
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Non-Hodgkin's Lymphoma (NHL)?
  • How many Non-Hodgkin's Lymphoma (NHL) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Non-Hodgkin's Lymphoma (NHL)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Non-Hodgkin's Lymphoma (NHL) market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Non-Hodgkin's Lymphoma (NHL)?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Non-Hodgkin's Lymphoma (NHL) therapies? 
  • What are the clinical studies going on for Non-Hodgkin's Lymphoma (NHL) and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Non-Hodgkin's Lymphoma (NHL)
  • How many patents are granted and pending for the emerging therapies for the treatment of Non-Hodgkin's Lymphoma (NHL)

1. Report Introduction

2. Non-Hodgkin's Lymphoma (NHL) 

2.1. Overview

2.2. History 

2.3. Non-Hodgkin's Lymphoma (NHL) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Non-Hodgkin's Lymphoma (NHL) Diagnosis 

2.6.1. Diagnostic Guidelines

3. Non-Hodgkin's Lymphoma Current Treatment Patterns

3.1. Non-Hodgkin's Lymphoma (NHL) Treatment Guidelines

4. Non-Hodgkin's Lymphoma - DelveInsight's Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Non-Hodgkin's Lymphoma (NHL) companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Non-Hodgkin's Lymphoma (NHL) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Non-Hodgkin's Lymphoma (NHL) Acquisition Analysis

5. Non-Hodgkin's Lymphoma Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. NHL Late Stage Products (Phase-III)

7. Non-Hodgkin's Lymphoma Mid Stage Products (Phase-II)

8. NHL Early Stage Products (Phase-I)

9. Non-Hodgkin's Lymphoma Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Hodgkin's Lymphoma Discontinued Products

13. Non-Hodgkin's Lymphoma Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Non-Hodgkin's Lymphoma Key Companies

15. Non-Hodgkin's Lymphoma Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Non-Hodgkin's Lymphoma Unmet Needs

18. Non-Hodgkin's Lymphoma Future Perspectives

19. Non-Hodgkin's Lymphoma Analyst Review  

20. Appendix

21. Non-Hodgkin's Lymphoma Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

Table 1: Non-Hodgkin's Lymphoma (NHL) Diagnostic Guidelines

Table 2: Non-Hodgkin's Lymphoma (NHL) Treatment Guidelines

Table 3: Assessment Summary

Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis

Table 5: Non-Hodgkin's Lymphoma (NHL) Acquisition Analysis

Table 6: Assessment by Phase of Development

Table 7: Assessment by Product Type (Mono / Combination)

Table 8: Assessment by Stage and Product Type

Table 9: Assessment by Route of Administration

Table 10: Assessment by Stage and Route of Administration

Table 11: Assessment by Molecule Type

Table 12: Assessment by Stage and Molecule Type

Table 13: Assessment by MOA

Table 14: Assessment by Stage and MOA

Table 15: Assessment by Target

Table 16: Assessment by Stage and Target

Table 17: Non-Hodgkin's Lymphoma (NHL) Late Stage Products (Phase-III)

Table 18: Non-Hodgkin's Lymphoma (NHL) Mid Stage Products (Phase-II)

Table 19: Non-Hodgkin's Lymphoma (NHL) Early Stage Products (Phase-I) 

Table 20: Pre-clinical and Discovery Stage Products

Table 21: Inactive Products

Table 22: Dormant Products

Table 23: Discontinued Products

Figure 1: Disease Overview

Figure 2: History

Figure 3: Symptoms

Figure 4: Causes

Figure 5: Pathophysiology

Figure 6: Diagnostic Guidelines

Figure 7: Treatment Guidelines

Figure 8: Non-Hodgkin's Lymphoma (NHL) companies collaborations, Licensing, Acquisition -Deal Value Trends

Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10: Non-Hodgkin's Lymphoma (NHL) Acquisition Analysis

Figure 11: Assessment by Phase of Development 

Figure 12: Assessment by Product Type (Mono / Combination)

Figure 13: Assessment by Stage and Product Type

Figure 14: Assessment by Route of Administration

Figure 15: Assessment by Stage and Route of Administration

Figure 16: Assessment by Molecule Type

Figure 17: Assessment by Stage and Molecule Type

Figure 18: Assessment by MOA

Figure 19: Assessment by Stage and MOA

Figure 20: Late Stage Products (Phase-III)

Figure 21: Mid Stage Products (Phase-II)

Figure 22: Early Stage Products (Phase-I)

Figure 23: Pre-clinical and Discovery Stage Products

Figure 24: Inactive Products

Figure 25: Dormant Products

Figure 26: Discontinued Products

Figure 27: Unmet Needs

1. ADC Therapeutics

2. Bristol-Myers Squibb

3. Roche

4. Amgen

5. Johnson & Johnson

6. Celgene Corp.

7. Mesoblast

8. Genmab

9. Novartis

10.  Teva Pharmaceutical Industries

11.  Karyopharm Therapeutics

12.  AB Science

13.  Genentech

14.  Eli Lilly and Company

15.  Rafael Pharmaceuticals

16.  IO Biotech

17.  ImmuneOnco Biopharma

18.  Chongqing Precision Biotech

19.  Rhizen Pharmaceuticals

20.  Nanjing Legend Biotech

21.  Tokalas

22.  Arvinas

23.  MorphoSys AG

24.  Shanghai Genechem

25.  Guiguidan Biomedicine (Zhongshan)

26.  Corvus Pharmaceuticals

27.  Evive Biotech

28.  Kite Pharma

29.  Pfizer 

30.  Gilead Sciences

31.  TG Therapeutics

32.  AstraZeneca

33.  Bayer HealthCare Pharmaceuticals

34.  Secura Bio

35.  BeiGene

36.  Xynomic Pharmaceuticals

37.  Merck & Co. Inc.

38.  Epizyme

39.  Nordic Nanovector

40.  Artiva Biotherapeutics, Inc.

41.  Timmune Biotech

42.  Forty Seven

43.  Acerta Pharma

44.  BioInvent International

45.  Adagene

46.  Juventas Cell Therapy

47.  SystImmune

48.  Molecular Templates

49.  Apollomics

50.  MEI Pharma

Forward to Friend

Need A Quote